Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239432 | 0.78 | LPL (0.38) | CSF1RAAK1 | |
| SCHEMBL23407744 | 0.76 | TTR (0.40) | TTRTRPV4SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL121746 | 0.74 | EGFR (0.42) | TTRSLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL23391525 | 0.74 | TTR (0.48) | TTRTRPV4SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23391597 | 0.74 | TTR (0.48) | TTRTRPV4SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL16655541 | 0.74 | CSF1R (0.37) | EGFRCSF1RAAK1 | |
| SCHEMBL5892464 | 0.74 | EGFR (0.47) | TTRTRPV4EGFRTSHRMAPK1 | |
| SCHEMBL16282205 | 0.74 | EGFR (0.47) | TRPV4SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL18186470 | 0.74 | LPL (0.35) | CSF1RAAK1 | |
| SCHEMBL1130429 | 0.74 | LPL (0.41) | TTRSLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063373-A1 | NOVEL METALLO-BETA-LACTAMASE INHIBITOR CREATED IN MULTI-DRUG RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR | Myongji University Industry and Academia Cooperation Foundation (KR) | 2022-09-28 | — | — | EP | disclosed |
| US-11395829-B2 | Inhibitors of metallo-beta-lactamases produced by multidrug-resistant bacteria | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2022-07-26 | — | — | US | disclosed |
| US-11395829-B2 | Inhibitors of metallo-beta-lactamases produced by multidrug-resistant bacteria | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2022-07-26 | — | — | US | disclosed |
| CN-113195505-A | Inhibitors of metallo-beta-lactamase produced by multi-drug resistant bacteria and methods of preparing the same | 明知大学校产学协力团 | 2021-07-30 | — | — | CN | disclosed |
| US-20210154216-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES PRODUCED BY MULTIDRUG-RESISTANT BACTERIA | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154216-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES PRODUCED BY MULTIDRUG-RESISTANT BACTERIA | MANBA, MGAM, GUSB | TTR 4399/4885TRPV4 4657/4885SLC6A4 4430/4885 |
| US-11395829-B2 | Inhibitors of metallo-beta-lactamases produced by multidrug-resistant bacteria | MANBA, MGAM, GUSB | TTR 4399/4885TRPV4 4657/4885SLC6A4 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.